Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Venetoclax,VtxStudy001,2022,USA,MDV,350,72,45,55,27.5,32,68,5,12,35,30,23,48,25,17,10,15,38,47,18,8,4,12,6,15,42,35,R-CHOP,DA-EPOCH-R,Rituximab,None,2,1,1,25,55,40,10,45,45,60,2
Venetoclax,VtxStudy002,2023,Canada,Claim Database,420,75,48,52,28.1,28,72,7,10,38,32,20,52,22,16,10,12,40,48,20,10,5,14,7,12,45,38,R-CHOP,Hyper-CVAD,Rituximab,None,3,2,1,28,58,42,12,42,46,65,3
Venetoclax,VtxStudy003,2023,UK,MDV,280,70,52,48,26.8,35,65,6,15,32,33,20,50,24,15,11,14,36,50,17,9,3,11,5,14,40,33,R-CHOP,DA-EPOCH-R,Rituximab,None,2,1,1,26,56,41,8,48,44,58,2
Venetoclax,VtxStudy004,2024,Germany,Claim Database,480,73,47,53,27.9,30,70,8,11,37,31,21,51,23,17,9,13,39,48,19,11,6,13,8,13,44,37,R-CHOP,Hyper-CVAD,Rituximab,None,3,2,1,27,57,43,11,43,46,63,3
